1239729-06-6

1239729-06-6 structure

Name: RP-5063
Chemical Name: Brilaroxazine
CAS Number: 1239729-06-6
Molecular Formula: C₂₂H₂₅Cl₂N₃O₃
Molecular Weight: 450.358
Catalog: Signaling Pathways GPCR/G Protein 5-HT Receptor
Create Date: 2020-01-11 18:56:34
Modify Date: 2024-01-08 18:18:54
RP-5063 (Brilaroxazine) is a multimodal dopamine and serotonin modulator with partial agonist activity at DA D2, D3, D4, 5-HT1A, and 5-HT2ARs, and antagonist activity at 5-HT2B, 5-HT6 and 5-HT7Rs; produces dose-dependent reductions in pulmonary blood vessel wall thickness and proportion of muscular vessels, blocks MCT-induced increases in the plasma cytokines TNFα, IL-1β, and IL-6 in vivo; prevents Sugen 5416-hypoxia-induced pulmonary arterial hypertension in rats; improves declarative memory and psychosis in mouse models of schizophrenia. Schizophrenia Phase 2 Clinical

Name	Brilaroxazine
Synonyms	6-{4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy}-2H-1,4-benzoxazin-3(4H)-one Brilaroxazine 2H-1,4-Benzoxazin-3(4H)-one, 6-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-

Description	RP-5063 (Brilaroxazine) is a multimodal dopamine and serotonin modulator with partial agonist activity at DA D2, D3, D4, 5-HT1A, and 5-HT2ARs, and antagonist activity at 5-HT2B, 5-HT6 and 5-HT7Rs; produces dose-dependent reductions in pulmonary blood vessel wall thickness and proportion of muscular vessels, blocks MCT-induced increases in the plasma cytokines TNFα, IL-1β, and IL-6 in vivo; prevents Sugen 5416-hypoxia-induced pulmonary arterial hypertension in rats; improves declarative memory and psychosis in mouse models of schizophrenia. Schizophrenia Phase 2 Clinical
References	References 1. Bhat L, et al. Eur J Pharmacol. 2017 Sep 5;810:83-91. 2. Rajagopal L, et al. Behav Brain Res. 2017 Aug 14;332:180-199. 3. Bhat L, et al. Eur J Pharmacol. 2017 Sep 5;810:92-99. View Related Products by Target Dopamine Receptor Schizophrenia